Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Affimed (AFMD) Misses Q2 EPS by 1c; CMO Marschner to Resign

Affimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update

August 10, 2016 7:30 AM EDT

HEIDELBERG, Germany, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended June 30, 2016 and provided a corporate update.

We continue to evolve our clinical development strategy, placing increased emphasis on developing our products as combination therapies and are evaluating several promising opportunities such as combining AFM13 with adoptive NK-cell therapy, said Dr. Adi Hoess, CEO of Affimed. To expand the target space for immune cell engagers, we have been exploring the... More